{"id":688696,"date":"2022-09-26T08:21:44","date_gmt":"2022-09-26T12:21:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/"},"modified":"2022-09-26T08:21:44","modified_gmt":"2022-09-26T12:21:44","slug":"htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/","title":{"rendered":"HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">TUCSON, Ariz., Sept.  26, 2022  (GLOBE NEWSWIRE) &#8212; \u00a0HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.<\/p>\n<p>John Lubniewski, HTG CEO will be a participant in the panel discussion, \u201cPredictive Biomarkers, Sequencing and Diagnostics, Oh My!\u201d at 9:50 am ET on September 28, 2022.<\/p>\n<p>For more information or to schedule a one-on-one meeting with management, please contact your Cantor Fitzgerald sales representative.<\/p>\n<p>\n        <strong>About HTG: <\/strong>\n      <\/p>\n<p>HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.<\/p>\n<p>Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG\u2019s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iDC_SHU1SXgA__bqwzsfgZRbEax5SukFJcgxEKgrjWQFlD6cCtQzgTgbM7q-ppgQLLzRMRy_gY872DDYiq4n6JTnYmB5J6vAVi__HvS4Uoc=\" rel=\"nofollow noopener\" target=\"_blank\">www.htgmolecular.com<\/a>.<\/p>\n<p>\n        <strong>HTG Investor Contact:<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>Ashley Robinson\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>LifeSci Advisors \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <br \/>Phone: (617) 430-7577\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wc3m0qZpGKwfI9bdsNR-b-pr2zVVmC4Pu0PJe_ifpxomB2xLuis6qqtIhQir96H5nCzhrtlHiwiFrtu82x-Mu5TFO6rw9lRgNQN-X0VS6SM=\" rel=\"nofollow noopener\" target=\"_blank\">arr@lifesciadvisors.com<\/a>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg5NSM1MTY3NzQwIzIwMTY4Nzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDY1MDBlYWItZDAwNi00NWVmLThiYzMtZTNlMjY3NmI5NDMzLTEwMjg0NTI=\/tiny\/HTG-Molecular-Diagnostics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TUCSON, Ariz., Sept. 26, 2022 (GLOBE NEWSWIRE) &#8212; \u00a0HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022. John Lubniewski, HTG CEO will be a participant in the panel discussion, \u201cPredictive Biomarkers, Sequencing and Diagnostics, Oh My!\u201d at 9:50 am ET on September 28, 2022. For more information or to schedule a one-on-one meeting with management, please contact your Cantor Fitzgerald sales representative. About HTG: HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-688696","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TUCSON, Ariz., Sept. 26, 2022 (GLOBE NEWSWIRE) &#8212; \u00a0HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022. John Lubniewski, HTG CEO will be a participant in the panel discussion, \u201cPredictive Biomarkers, Sequencing and Diagnostics, Oh My!\u201d at 9:50 am ET on September 28, 2022. For more information or to schedule a one-on-one meeting with management, please contact your Cantor Fitzgerald sales representative. About HTG: HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide &hellip; Continue reading &quot;HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-26T12:21:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg5NSM1MTY3NzQwIzIwMTY4Nzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference\",\"datePublished\":\"2022-09-26T12:21:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\\\/\"},\"wordCount\":215,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTg5NSM1MTY3NzQwIzIwMTY4Nzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\\\/\",\"name\":\"HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTg5NSM1MTY3NzQwIzIwMTY4Nzk=\",\"datePublished\":\"2022-09-26T12:21:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTg5NSM1MTY3NzQwIzIwMTY4Nzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MTg5NSM1MTY3NzQwIzIwMTY4Nzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/","og_locale":"en_US","og_type":"article","og_title":"HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk","og_description":"TUCSON, Ariz., Sept. 26, 2022 (GLOBE NEWSWIRE) &#8212; \u00a0HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022. John Lubniewski, HTG CEO will be a participant in the panel discussion, \u201cPredictive Biomarkers, Sequencing and Diagnostics, Oh My!\u201d at 9:50 am ET on September 28, 2022. For more information or to schedule a one-on-one meeting with management, please contact your Cantor Fitzgerald sales representative. About HTG: HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide &hellip; Continue reading \"HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-26T12:21:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg5NSM1MTY3NzQwIzIwMTY4Nzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference","datePublished":"2022-09-26T12:21:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/"},"wordCount":215,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg5NSM1MTY3NzQwIzIwMTY4Nzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/","name":"HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg5NSM1MTY3NzQwIzIwMTY4Nzk=","datePublished":"2022-09-26T12:21:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg5NSM1MTY3NzQwIzIwMTY4Nzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MTg5NSM1MTY3NzQwIzIwMTY4Nzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/htg-molecular-diagnostics-to-participate-in-the-cantor-fitzgerald-oncology-hematology-hemeonc-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology &amp; HemeOnc Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=688696"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688696\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=688696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=688696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=688696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}